We are live on ! Find out more
ACM

AIHC Capital Management Portfolio holdings

AUM $104M
This Fund
S&P 500
This Quarter Est. Return
+27.66%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$120M
AUM Growth
+$13M
Cap. Flow
-$4.45M
Cap. Flow %
-3.72%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
1
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$27.9M
2
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$6.19M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$16.6M
2
AVBP icon
ArriVent BioPharma
AVBP
+$13M
3
RVMD icon
Revolution Medicines
RVMD
+$7.21M
4
COGT icon
Cogent Biosciences
COGT
+$1.79M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$44.6B
$80.6M 67.37%
828,974
-71,418
-8% -$7.21M
ORIC icon
2
Oric Pharmaceuticals
ORIC
$1.37B
$31.2M 26.04%
+2,459,551
New +$27.9M
NBP
3
NovaBridge Biosciences American Depositary Shares
NBP
$213M
$5.57M 4.65%
2,262,933
+1,848,954
+447% +$6.19M
COGT icon
4
Cogent Biosciences
COGT
$6.02B
$1.98M 1.65%
51,402
-48,598
-49% -$1.79M
KRRO icon
5
Korro Bio
KRRO
$190M
$343K 0.29%
30,265
– –
PTGX icon
6
Protagonist Therapeutics
PTGX
$9.34B
– –
-189,823
Closed -$16.6M
AVBP icon
7
ArriVent BioPharma
AVBP
$1.49B
– –
-644,788
Closed -$13M

Similar funds

TPW
TOP Private Wealth Glastonbury, Connecticut $104M AUM
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $104M AUM
XFP
Xena Financial Planning Portland, Oregon $104M AUM
SFG
Strategic Financial Group Grand Haven, Michigan $104M AUM
JRSI
Jeter Robert S II $104M AUM
VA
Verdad Advisers Boston, Massachusetts $104M AUM
IAP
Indie Asset Partners Carmel, Indiana $104M AUM 31.76% 1-Year Est. Return
GAM
Gritstone Asset Management Bethesda, Maryland $104M AUM 6.03% 1-Year Est. Return

AIHC Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, AIHC Capital Management held 7 positions worth $120M, up 12% from $107M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

AIHC Capital Management withdrew a net $4.45M in Q1 2026, closing 2 positions and reducing 2 holdings. Its most notable exit was Protagonist Therapeutics, an estimated $16.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, AIHC Capital Management opened a new position in Oric Pharmaceuticals worth $31.2M.

  • AIHC Capital Management's largest Q1 2026 buy was Oric Pharmaceuticals: 2,459,551 shares worth $31.2M.
  • AIHC Capital Management added most to NovaBridge Biosciences American Depositary Shares in Q1 2026, an estimated $6.19M increase.
  • AIHC Capital Management's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $7.21M.
  • AIHC Capital Management fully exited Protagonist Therapeutics in Q1 2026, selling an estimated $16.6M.
  • AIHC Capital Management's ten largest holdings make up 100% of its $120M portfolio in Q1 2026.
  • AIHC Capital Management opened 1 new position and closed 2 in Q1 2026.
  • AIHC Capital Management's portfolio value rose 12% quarter-over-quarter to $120M.

Based on AIHC Capital Management's 13F filing for Q1 2026, filed 8 May 2026.